<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35659112</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>33</StartPage><MedlinePgn>33</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">33</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-022-00307-z</ELocationID><Abstract><AbstractText>Most neurodegenerative disorders are diseases of protein homeostasis, with misfolded aggregates accumulating. The neurodegenerative process is mediated by numerous metabolic pathways, most of which lead to apoptosis. In recent years, hydrophilic bile acids, particularly tauroursodeoxycholic acid (TUDCA), have shown important anti-apoptotic and neuroprotective activities, with numerous experimental and clinical evidence suggesting their possible therapeutic use as disease-modifiers in neurodegenerative diseases. Experimental evidence on the mechanisms underlying TUDCA's neuroprotective action derives from animal models of Alzheimer's disease, Parkinson's disease, Huntington's diseases, amyotrophic lateral sclerosis (ALS) and cerebral ischemia. Preclinical studies indicate that TUDCA exerts its effects not only by regulating and inhibiting the apoptotic cascade, but also by reducing oxidative stress, protecting the mitochondria, producing an anti-neuroinflammatory action, and acting as a chemical chaperone to maintain the stability and correct folding of proteins. Furthermore, data from phase II clinical trials have shown TUDCA to be safe and a potential disease-modifier in ALS. ALS is the first neurodegenerative disease being treated with hydrophilic bile acids. While further clinical evidence is being accumulated for the other diseases, TUDCA stands as a promising treatment for neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalaf</LastName><ForeName>Kareem</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tornese</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocco</LastName><ForeName>Antoniangela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5864-0006</Identifier><AffiliationInfo><Affiliation>Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. alberto.albanese@unicatt.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>755094</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance></Chemical><Chemical><RegistryNumber>516-35-8</RegistryNumber><NameOfSubstance UI="D013655">Taurochenodeoxycholic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>60EUX8MN5X</RegistryNumber><NameOfSubstance UI="C031655">ursodoxicoltaurine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001647" MajorTopicYN="N">Bile Acids and Salts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013655" MajorTopicYN="N">Taurochenodeoxycholic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Bile acids</Keyword><Keyword MajorTopicYN="N">Disease-modifying</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Neurodegeneration</Keyword><Keyword MajorTopicYN="N">Neuroprotection</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Tauroursodeoxycholic acid</Keyword><Keyword MajorTopicYN="N">Ursodeoxycholic acid</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>10</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35659112</ArticleId><ArticleId IdType="pmc">PMC9166453</ArticleId><ArticleId IdType="doi">10.1186/s40035-022-00307-z</ArticleId><ArticleId IdType="pii">10.1186/s40035-022-00307-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1332&#x2013;1340. doi: 10.1038/s41593-018-0235-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId><ArticleId IdType="pmc">PMC6432913</ArticleId><ArticleId IdType="pubmed">30250260</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Hardy J, Duff KE. Selective vulnerability in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1350&#x2013;1358. doi: 10.1038/s41593-018-0221-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0221-2</ArticleId><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10(4):a033118. doi: 10.1101/cshperspect.a033118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a033118</ArticleId><ArticleId IdType="pmc">PMC5880171</ArticleId><ArticleId IdType="pubmed">28716886</ArticleId></ArticleIdList></Reference><Reference><Citation>Sureda FX, Junyent F, Verdaguer E, Auladell C, Pelegri C, Vilaplana J, et al. Antiapoptotic drugs: a therapautic strategy for the prevention of neurodegenerative diseases. Curr Pharm Des. 2011;17(3):230&#x2013;245. doi: 10.2174/138161211795049732.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161211795049732</ArticleId><ArticleId IdType="pubmed">21348832</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SM, DeMorrow S. Bile acid signaling in neurodegenerative and neurological disorders. Int J Mol Sci. 2020;21(17):5982. doi: 10.3390/ijms21175982.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21175982</ArticleId><ArticleId IdType="pmc">PMC7503576</ArticleId><ArticleId IdType="pubmed">32825239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in liver diseases: a review of their mechanisms of action and clinical applications. Handb Exp Pharmacol. 2019;256:237&#x2013;264. doi: 10.1007/164_2019_241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/164_2019_241</ArticleId><ArticleId IdType="pubmed">31236688</ArticleId></ArticleIdList></Reference><Reference><Citation>Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001;171(2):351&#x2013;360. doi: 10.1006/exnr.2001.7755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7755</ArticleId><ArticleId IdType="pubmed">11573988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003;100(10):6087&#x2013;6092. doi: 10.1073/pnas.1031632100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1031632100</ArticleId><ArticleId IdType="pmc">PMC156330</ArticleId><ArticleId IdType="pubmed">12721362</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry GJ, Rodrigues CM, Aranha MM, Hilbert SJ, Davey C, Kelkar P, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010;33(1):17&#x2013;21. doi: 10.1097/WNF.0b013e3181c47569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNF.0b013e3181c47569</ArticleId><ArticleId IdType="pubmed">19935406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front Neurosci. 2017;11:617. doi: 10.3389/fnins.2017.00617.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00617</ArticleId><ArticleId IdType="pmc">PMC5681992</ArticleId><ArticleId IdType="pubmed">29163019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH, Othman MHD. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. Biomolecules. 2018;8(4):159. doi: 10.3390/biom8040159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom8040159</ArticleId><ArticleId IdType="pmc">PMC6316857</ArticleId><ArticleId IdType="pubmed">30486474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6. doi: 10.1186/s40035-017-0077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0077-5</ArticleId><ArticleId IdType="pmc">PMC5348787</ArticleId><ArticleId IdType="pubmed">28293421</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeromin A, Bowser R. Biomarkers in neurodegenerative diseases. Adv Neurobiol. 2017;15:491&#x2013;528. doi: 10.1007/978-3-319-57193-5_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-57193-5_20</ArticleId><ArticleId IdType="pubmed">28674995</ArticleId></ArticleIdList></Reference><Reference><Citation>Didonna A, Opal P. The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders. Mol Neurodegener. 2019;14(1):19. doi: 10.1186/s13024-019-0318-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0318-4</ArticleId><ArticleId IdType="pmc">PMC6524292</ArticleId><ArticleId IdType="pubmed">31097008</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol. 2008;64(Suppl 2):S101&#x2013;S110.</Citation><ArticleIdList><ArticleId IdType="pubmed">19127580</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Future strategies for neuroprotection in Parkinson's disease. Neurodegener Dis. 2010;7(1&#x2013;3):210&#x2013;212. doi: 10.1159/000295666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000295666</ArticleId><ArticleId IdType="pubmed">20224288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH. Neuroprotection in Parkinson's disease. Parkinsonism Relat Disord. 2009;15(Suppl 4):S41&#x2013;S43. doi: 10.1016/S1353-8020(09)70834-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(09)70834-X</ArticleId><ArticleId IdType="pubmed">20123556</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima MT, Islam Z, Ahmad E, Salahuddin P. Emerging targets and latest proteomics based therapeutic approaches in neurodegenerative diseases. Curr Protein Pept Sci. 2018;19(9):858&#x2013;875. doi: 10.2174/1389203718666170731114757.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203718666170731114757</ArticleId><ArticleId IdType="pubmed">28762306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018;21(10):1300&#x2013;1309. doi: 10.1038/s41593-018-0237-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0237-7</ArticleId><ArticleId IdType="pmc">PMC6278826</ArticleId><ArticleId IdType="pubmed">30258237</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59(3):559&#x2013;562. doi: 10.1002/ana.20789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20789</ArticleId><ArticleId IdType="pubmed">16489611</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328(3):176&#x2013;183. doi: 10.1056/NEJM199301213280305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199301213280305</ArticleId><ArticleId IdType="pubmed">8417384</ArticleId></ArticleIdList></Reference><Reference><Citation>Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54(1):93&#x2013;101. doi: 10.1002/ana.10609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10609</ArticleId><ArticleId IdType="pubmed">12838524</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653&#x2013;1661. doi: 10.1001/jama.287.13.1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.287.13.1653</ArticleId><ArticleId IdType="pubmed">11926889</ArticleId></ArticleIdList></Reference><Reference><Citation>Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002;99(16):10671&#x2013;10676. doi: 10.1073/pnas.162362299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162362299</ArticleId><ArticleId IdType="pmc">PMC125009</ArticleId><ArticleId IdType="pubmed">12149470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Spellman SR, Sola S, Grande AW, Linehan-Stieers C, Low WC, et al. Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab. 2002;22(4):463&#x2013;471. doi: 10.1097/00004647-200204000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004647-200204000-00010</ArticleId><ArticleId IdType="pubmed">11919517</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpini G, Kanno N, Phinizy JL, Glaser S, Francis H, Taffetani S, et al. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G973&#x2013;G982. doi: 10.1152/ajpgi.00270.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00270.2003</ArticleId><ArticleId IdType="pubmed">14701718</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721&#x2013;1734. doi: 10.1194/jlr.R900011-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R900011-JLR200</ArticleId><ArticleId IdType="pmc">PMC2724780</ArticleId><ArticleId IdType="pubmed">19417220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCalpha-mediated MKP-1 induction. Cardiovasc Res. 2011;92(2):307&#x2013;316. doi: 10.1093/cvr/cvr219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvr219</ArticleId><ArticleId IdType="pubmed">21840882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusl T, Vennegeerts T, Wimmer R, Denk GU, Beuers U, Rust C. Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. Biochem Biophys Res Commun. 2008;367(1):208&#x2013;212. doi: 10.1016/j.bbrc.2007.12.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.12.122</ArticleId><ArticleId IdType="pubmed">18164257</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon YM, Lee JH, Yun SP, Han YS, Yun CW, Lee HJ, et al. Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein. Sci Rep. 2016;6:39838. doi: 10.1038/srep39838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39838</ArticleId><ArticleId IdType="pmc">PMC5177936</ArticleId><ArticleId IdType="pubmed">28004805</ArticleId></ArticleIdList></Reference><Reference><Citation>Marizzoni M, Provasi S, Cattaneo A, Frisoni GB. Microbiota and neurodegenerative diseases. Curr Opin Neurol. 2017;30(6):630&#x2013;638. doi: 10.1097/WCO.0000000000000496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000496</ArticleId><ArticleId IdType="pubmed">28906270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar SR, Banerjee S. Gut microbiota in neurodegenerative disorders. J Neuroimmunol. 2019;328:98&#x2013;104. doi: 10.1016/j.jneuroim.2019.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2019.01.004</ArticleId><ArticleId IdType="pubmed">30658292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridlon JM, Bajaj JS. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharm Sin B. 2015;5(2):99&#x2013;105. doi: 10.1016/j.apsb.2015.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2015.01.006</ArticleId><ArticleId IdType="pmc">PMC4629220</ArticleId><ArticleId IdType="pubmed">26579434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulak A. Bile acids as key modulators of the brain-gut-microbiota axis in Alzheimer's disease. J Alzheimers Dis. 2021;84(2):461&#x2013;477. doi: 10.3233/JAD-210608.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-210608</ArticleId><ArticleId IdType="pmc">PMC8673511</ArticleId><ArticleId IdType="pubmed">34569953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson T, Caporaso JG, Yellowhair M, Bokulich NA, Padi M, Roe DJ, et al. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. Cancer Med. 2019;8(2):617&#x2013;628. doi: 10.1002/cam4.1965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1965</ArticleId><ArticleId IdType="pmc">PMC6382922</ArticleId><ArticleId IdType="pubmed">30652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Sola S, Silva R, Brites D. Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization. Mol Med. 2000;6(11):936&#x2013;946. doi: 10.1007/BF03401828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03401828</ArticleId><ArticleId IdType="pmc">PMC1949925</ArticleId><ArticleId IdType="pubmed">11147571</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaral JD, Castro RE, Sola S, Steer CJ, Rodrigues CM. p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J Biol Chem. 2007;282(47):34250&#x2013;34259. doi: 10.1074/jbc.M704075200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M704075200</ArticleId><ArticleId IdType="pubmed">17881359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CM. Inhibition of the E2F&#x2013;1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem. 2004;90(3):567&#x2013;575. doi: 10.1111/j.1471-4159.2004.02517.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02517.x</ArticleId><ArticleId IdType="pubmed">15255934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola S, Castro RE, Laires PA, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med. 2003;9(9&#x2013;12):226&#x2013;234. doi: 10.2119/2003-00042.Rodrigues.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/2003-00042.Rodrigues</ArticleId><ArticleId IdType="pmc">PMC1430980</ArticleId><ArticleId IdType="pubmed">15208744</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionisio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues CM. Amyloid-beta pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging. 2015;36(1):228&#x2013;240. doi: 10.1016/j.neurobiolaging.2014.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.08.034</ArticleId><ArticleId IdType="pubmed">25443293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho RM, Borralho PM, Castro RE, Sola S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neurochem. 2006;98(5):1610&#x2013;1618. doi: 10.1111/j.1471-4159.2006.04007.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04007.x</ArticleId><ArticleId IdType="pubmed">16923170</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana RJ, Nunes AF, Castro RE, Ramalho RM, Meyerson J, Fossati S, et al. Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. Cell Mol Life Sci. 2009;66(6):1094&#x2013;1104. doi: 10.1007/s00018-009-8746-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-009-8746-x</ArticleId><ArticleId IdType="pmc">PMC2760857</ArticleId><ArticleId IdType="pubmed">19189048</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Sola S, Brito MA, Brondino CD, Brites D, Moura JJ. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun. 2001;281(2):468&#x2013;474. doi: 10.1006/bbrc.2001.4370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2001.4370</ArticleId><ArticleId IdType="pubmed">11181071</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med. 2008;14(2):54&#x2013;62. doi: 10.1016/j.molmed.2007.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2007.12.001</ArticleId><ArticleId IdType="pubmed">18218342</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A. 2003;100(17):10032&#x2013;10037. doi: 10.1073/pnas.1630428100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1630428100</ArticleId><ArticleId IdType="pmc">PMC187753</ArticleId><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusaczuk M. Tauroursodeoxycholate-bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives. Cells. 2019;8(12):1471. doi: 10.3390/cells8121471.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8121471</ArticleId><ArticleId IdType="pmc">PMC6952947</ArticleId><ArticleId IdType="pubmed">31757001</ArticleId></ArticleIdList></Reference><Reference><Citation>Omura T, Asari M, Yamamoto J, Oka K, Hoshina C, Maseda C, et al. Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells. Biochem Biophys Res Commun. 2013;432(4):689&#x2013;694. doi: 10.1016/j.bbrc.2013.01.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2013.01.131</ArticleId><ArticleId IdType="pubmed">23416354</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Harg JM, Nolle A, Zwart R, Boerema AS, van Haastert ES, Strijkstra AM, et al. The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death Dis. 2014;5:e1393. doi: 10.1038/cddis.2014.354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.354</ArticleId><ArticleId IdType="pmc">PMC4454326</ArticleId><ArticleId IdType="pubmed">25165879</ArticleId></ArticleIdList></Reference><Reference><Citation>Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta. 2008;1782(9):517&#x2013;522. doi: 10.1016/j.bbadis.2008.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2008.05.005</ArticleId><ArticleId IdType="pubmed">18572024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho RM, Nunes AF, Dias RB, Amaral JD, Lo AC, D'Hooge R, et al. Tauroursodeoxycholic acid suppresses amyloid beta-induced synaptic toxicity in vitro and in APP/PS1 mice. Neurobiol Aging. 2013;34(2):551&#x2013;561. doi: 10.1016/j.neurobiolaging.2012.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.04.018</ArticleId><ArticleId IdType="pubmed">22621777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CM, D'Hooge R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol Dis. 2013;50:21&#x2013;29. doi: 10.1016/j.nbd.2012.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.09.003</ArticleId><ArticleId IdType="pubmed">22974733</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunez I, Tasset I, Perez-De La Cruz V, Santamaria A. 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future. Molecules. 2010;15(2):878&#x2013;916. doi: 10.3390/molecules15020878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules15020878</ArticleId><ArticleId IdType="pmc">PMC6263191</ArticleId><ArticleId IdType="pubmed">20335954</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, et al. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem. 2000;75(6):2368&#x2013;2379. doi: 10.1046/j.1471-4159.2000.0752368.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0752368.x</ArticleId><ArticleId IdType="pubmed">11080188</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia SJ, Tan EK, Chao YX. Historical perspective: models of Parkinson's disease. Int J Mol Sci. 2020;21(7):2464. doi: 10.3390/ijms21072464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21072464</ArticleId><ArticleId IdType="pmc">PMC7177377</ArticleId><ArticleId IdType="pubmed">32252301</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan WM, Rodrigues CM, Zhao LR, Steer CJ, Low WC. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant. 2002;11:195&#x2013;205. doi: 10.3727/096020198389960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096020198389960</ArticleId><ArticleId IdType="pubmed">12075985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem. 2005;280(52):42655&#x2013;42668. doi: 10.1074/jbc.M505910200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505910200</ArticleId><ArticleId IdType="pmc">PMC3910375</ArticleId><ArticleId IdType="pubmed">16239214</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, et al. Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease. Mol Neurobiol. 2012;46(2):475&#x2013;486. doi: 10.1007/s12035-012-8295-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8295-4</ArticleId><ArticleId IdType="pubmed">22773138</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira S, Fonseca I, Nunes MJ, Rosa A, Lemos L, Rodrigues E, et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease. Exp Neurol. 2017;295:77&#x2013;87. doi: 10.1016/j.expneurol.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.05.009</ArticleId><ArticleId IdType="pubmed">28552716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa AI, Fonseca I, Nunes MJ, Moreira S, Rodrigues E, Carvalho AN, et al. Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease. Biochim Biophys Acta Mol Basis Dis. 2017;1863(9):2171&#x2013;2181. doi: 10.1016/j.bbadis.2017.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2017.06.004</ArticleId><ArticleId IdType="pubmed">28583715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa AI, Duarte-Silva S, Silva-Fernandes A, Nunes MJ, Carvalho AN, Rodrigues E, et al. Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease. Mol Neurobiol. 2018;55(12):9139&#x2013;9155. doi: 10.1007/s12035-018-1062-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1062-4</ArticleId><ArticleId IdType="pubmed">29651747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes MO, Rosa AI, Carvalho AN, Nunes MJ, Dionisio P, Rodrigues E, et al. Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy. Mol Cell Neurosci. 2019;96:1&#x2013;9. doi: 10.1016/j.mcn.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2019.01.003</ArticleId><ArticleId IdType="pubmed">30771505</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, Ravits J. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin. 2015;33(4):855&#x2013;876. doi: 10.1016/j.ncl.2015.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitzer C, Kruger C, Plaas C, Kirsch F, Dittgen T, Muller R, et al. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain. 2008;131(Pt 12):3335&#x2013;3347. doi: 10.1093/brain/awn243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn243</ArticleId><ArticleId IdType="pmc">PMC2639207</ArticleId><ArticleId IdType="pubmed">18835867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol. 2001;27(4):257&#x2013;274. doi: 10.1046/j.0305-1846.2001.00332.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0305-1846.2001.00332.x</ArticleId><ArticleId IdType="pubmed">11532157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thams S, Lowry ER, Larraufie MH, Spiller KJ, Li H, Williams DJ, et al. A stem cell-based screening platform identifies compounds that desensitize motor neurons to endoplasmic reticulum stress. Mol Ther. 2019;27(1):87&#x2013;101. doi: 10.1016/j.ymthe.2018.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.10.010</ArticleId><ArticleId IdType="pmc">PMC6318783</ArticleId><ArticleId IdType="pubmed">30446391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian KY, Jin HF, Sun W, Sun YJ. DCA can improve the ACI-induced neurological impairment through negative regulation of Nrf2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(1):343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">30657576</ArticleId></ArticleIdList></Reference><Reference><Citation>Colecchia A, Mazzella G, Sandri L, Azzaroli F, Magliuolo M, Simoni P, et al. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J Gastroenterol. 2006;12(33):5336&#x2013;5343. doi: 10.3748/wjg.v12.i33.5336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i33.5336</ArticleId><ArticleId IdType="pmc">PMC4088201</ArticleId><ArticleId IdType="pubmed">16981264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Jang DK, Yoo MW, Hwang SH, Ryu SY, Kwon OK, et al. Efficacy and safety of ursodeoxycholic acid for the prevention of gallstone formation after gastrectomy in patients with gastric cancer: The PEGASUS-D randomized clinical trial. JAMA Surg. 2020;155(8):703&#x2013;711. doi: 10.1001/jamasurg.2020.1501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2020.1501</ArticleId><ArticleId IdType="pmc">PMC7301302</ArticleId><ArticleId IdType="pubmed">32584935</ArticleId></ArticleIdList></Reference><Reference><Citation>Petroni ML, Jazrawi RP, Pazzi P, Lanzini A, Zuin M, Pigozzi MG, et al. Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group. Aliment Pharmacol Ther. 2001;15(1):123&#x2013;128. doi: 10.1046/j.1365-2036.2001.00853.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2001.00853.x</ArticleId><ArticleId IdType="pubmed">11136285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano LA, Cancado ELR, Chaves CE, Madeira MCV, Katayose JT, Nabeshima MA, et al. A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis. BMC Gastroenterol. 2020;20(1):253. doi: 10.1186/s12876-020-01399-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-020-01399-5</ArticleId><ArticleId IdType="pmc">PMC7406387</ArticleId><ArticleId IdType="pubmed">32758152</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopf C, Grieshaber R, Hartmann H, Hinrichsen H, Eisold M, Cordes HJ, et al. Therapeutic equivalence of ursodeoxycholic acid tablets and ursodeoxycholic acid capsules for the treatment of primary biliary cirrhosis. Clin Pharmacol Drug Dev. 2013;2(3):231&#x2013;236. doi: 10.1002/cpdd.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.24</ArticleId><ArticleId IdType="pubmed">27121784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000;32(4):561&#x2013;566. doi: 10.1016/S0168-8278(00)80216-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(00)80216-0</ArticleId><ArticleId IdType="pubmed">10782903</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. 1996;41(4):809&#x2013;815. doi: 10.1007/BF02213140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02213140</ArticleId><ArticleId IdType="pubmed">8674405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Zeng M, Han Y, Yan H, Tang H, Sheng J, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore) 2016;95(47):e5391. doi: 10.1097/MD.0000000000005391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000005391</ArticleId><ArticleId IdType="pmc">PMC5134868</ArticleId><ArticleId IdType="pubmed">27893675</ArticleId></ArticleIdList></Reference><Reference><Citation>Larghi A, Crosignani A, Battezzati PM, De Valle G, Allocca M, Invernizzi P, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther. 1997;11(2):409&#x2013;414. doi: 10.1046/j.1365-2036.1997.124295000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.124295000.x</ArticleId><ArticleId IdType="pubmed">9146783</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464&#x2013;1472. doi: 10.1053/j.gastro.2005.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2005.08.017</ArticleId><ArticleId IdType="pubmed">16285948</ArticleId></ArticleIdList></Reference><Reference><Citation>Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Farkkila M, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549&#x2013;558. doi: 10.1016/j.jhep.2017.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2017.05.009</ArticleId><ArticleId IdType="pubmed">28529147</ArticleId></ArticleIdList></Reference><Reference><Citation>Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut. 2007;56(12):1747&#x2013;1753. doi: 10.1136/gut.2007.120956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2007.120956</ArticleId><ArticleId IdType="pmc">PMC2095694</ArticleId><ArticleId IdType="pubmed">17573387</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, et al. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technol Med Sci. 2013;33(2):189&#x2013;194. doi: 10.1007/s11596-013-1095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11596-013-1095-x</ArticleId><ArticleId IdType="pubmed">23592128</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Agnolo HM, Kievit W, Takkenberg RB, Riano I, Bujanda L, Neijenhuis MK, et al. Ursodeoxycholic acid in advanced polycystic liver disease: a phase 2 multicenter randomized controlled trial. J Hepatol. 2016;65(3):601&#x2013;607. doi: 10.1016/j.jhep.2016.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2016.05.009</ArticleId><ArticleId IdType="pubmed">27212247</ArticleId></ArticleIdList></Reference><Reference><Citation>Joutsiniemi T, Timonen S, Leino R, Palo P, Ekblad U. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Arch Gynecol Obstet. 2014;289(3):541&#x2013;547. doi: 10.1007/s00404-013-2995-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-013-2995-5</ArticleId><ArticleId IdType="pubmed">23978872</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, et al. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract. 2016;70(4):302&#x2013;311. doi: 10.1111/ijcp.12790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.12790</ArticleId><ArticleId IdType="pmc">PMC5071730</ArticleId><ArticleId IdType="pubmed">26997458</ArticleId></ArticleIdList></Reference><Reference><Citation>Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. 2012;27(2):200&#x2013;206. doi: 10.3346/jkms.2012.27.2.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2012.27.2.200</ArticleId><ArticleId IdType="pmc">PMC3271295</ArticleId><ArticleId IdType="pubmed">22323869</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, Lalli S, Monsurro MR, Sagnelli A, Taiello AC, Reggiori B, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45&#x2013;52. doi: 10.1111/ene.12664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12664</ArticleId><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Tornese P, Lalli S, Cocco A, Albanese A. Review of disease-modifying drug trials in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022;93:521&#x2013;529. doi: 10.1136/jnnp-2021-328470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328470</ArticleId><ArticleId IdType="pubmed">35228271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur B, Bhat A, Chakraborty R, Adlakha K, Sengupta S, Roy S, et al. Proteomic profile of 4-PBA treated human neuronal cells during ER stress. Mol Omics. 2018;14(1):53&#x2013;63. doi: 10.1039/C7MO00114B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7MO00114B</ArticleId><ArticleId IdType="pubmed">29570205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93(5):1087&#x2013;1098. doi: 10.1111/j.1471-4159.2005.03077.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03077.x</ArticleId><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler. 2009;10(2):85&#x2013;94. doi: 10.1080/17482960802226148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802226148</ArticleId><ArticleId IdType="pubmed">18618304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH, Jr, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99&#x2013;106. doi: 10.1080/17482960802320487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802320487</ArticleId><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137&#x2013;1140. doi: 10.1126/science.1128294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1128294</ArticleId><ArticleId IdType="pmc">PMC4741373</ArticleId><ArticleId IdType="pubmed">16931765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30(3):332&#x2013;338. doi: 10.1097/MOG.0000000000000057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000057</ArticleId><ArticleId IdType="pmc">PMC4215539</ArticleId><ArticleId IdType="pubmed">24625896</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ. 1999;6(9):842&#x2013;854. doi: 10.1038/sj.cdd.4400560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4400560</ArticleId><ArticleId IdType="pubmed">10510466</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe IN, et al. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology. 2002;36(1):49&#x2013;54. doi: 10.1053/jhep.2002.34511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2002.34511</ArticleId><ArticleId IdType="pubmed">12085348</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002;36(3):592&#x2013;601. doi: 10.1053/jhep.2002.35441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2002.35441</ArticleId><ArticleId IdType="pubmed">12198651</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoemaker MH, Gommans WM, Conde de la Rosa L, Homan M, Klok P, Trautwein C, et al. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation. J Hepatol. 2003;39(2):153&#x2013;161. doi: 10.1016/S0168-8278(03)00214-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(03)00214-9</ArticleId><ArticleId IdType="pubmed">12873810</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, Gores GJ. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem. 2000;275(26):20210&#x2013;20216. doi: 10.1074/jbc.M909992199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M909992199</ArticleId><ArticleId IdType="pubmed">10770953</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology. 2004;39(6):1563&#x2013;1573. doi: 10.1002/hep.20246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20246</ArticleId><ArticleId IdType="pubmed">15185297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sola S, Amaral JD, Castro RE, Ramalho RM, Borralho PM, Kren BT, et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology. 2005;42(4):925&#x2013;934. doi: 10.1002/hep.20870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20870</ArticleId><ArticleId IdType="pubmed">16175607</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusl T, Wild N, Vennegeerts T, Wimmer R, Goke B, Brand S, et al. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun. 2008;371(3):441&#x2013;445. doi: 10.1016/j.bbrc.2008.04.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.04.113</ArticleId><ArticleId IdType="pubmed">18452708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>